American Regent v. Xiromed: Selenious Acid IV Patent Case Consolidated in 21 Days
American Regent, Inc. filed suit against Xiromed, LLC in the District of New Jersey over US12150957B2, asserting infringement by Xiromed’s generic selenious acid 600 mcg/10 mL intravenous solution. The case was consolidated within 21 days into the broader In re Selenious Acid Litigation alongside 12 parallel actions against major generics manufacturers.
Mass consolidation of selenious acid ANDA suits signals coordinated enforcement strategy
On December 13, 2024, American Regent, Inc. (ARI) filed Civil Action No. 2:24-cv-11130 against Xiromed, LLC and Xiromed Pharma España, S.L. in the U.S. District Court for the District of New Jersey, asserting infringement of US12150957B2. The patent covers ARI’s selenious acid intravenous solution — a parenteral nutrition product delivering 600 mcg of selenium per 10 mL — which Xiromed’s ANDA product is alleged to replicate.
The case closed on January 3, 2025, just 21 days after filing, when all parties jointly requested consolidation into the already-pending In re Selenious Acid Litigation (Civil Action No. 2:24-cv-7791). The consolidation order merged this action with 12 other parallel suits ARI filed simultaneously on December 13 against defendants including Accord Healthcare, Cipla, Dr. Reddy’s, Hikma, Sun Pharma, and Zydus, among others. All future filings are to proceed under the consolidated caption in Civil Action No. 24-7791.
The 21-day closure reflects procedural efficiency rather than any substantive resolution — no merits rulings, no claim construction, and no damages determinations have been made in this individual docket. The simultaneous filing against 12+ generic manufacturers on the same date is consistent with a Hatch-Waxman paragraph IV certification response, where the 30-month stay clock incentivises rapid, coordinated filing. What remains unknown from the public record is the specific ANDA numbers at issue, the precise claim scope contested, and the litigation posture of each individual defendant within the consolidated proceeding.
Filing to Case Consolidated in 21 days
21 days — resolved via consolidation order, among the fastest case closures in pharma ANDA litigation
Case consolidated: what the transfer into In re Selenious Acid Litigation means
Consolidation merges proceedings — not a dismissal on the merits
Case consolidation under Fed. R. Civ. P. 42(a) combines actions sharing common questions of law or fact into a single coordinated proceeding. This case was not dismissed — it was absorbed into In re Selenious Acid Litigation (2:24-cv-7791). All claims against Xiromed remain live; they will now be litigated under a single docket alongside parallel claims against 12 other generic defendants.
No merits ruling madeSingle docket, shared schedule — efficiency for the court, complexity for defendants
Consolidation centralises discovery, claim construction, and scheduling before one judge. For Xiromed, this means shared briefing schedules and potentially coordinated invalidity arguments with co-defendants. However, infringement and damages analysis typically remains defendant-specific. Xiromed’s exposure under US12150957B2 is not reduced by consolidation — it is simply adjudicated alongside that of 12 other generic challengers.
Claims against Xiromed remain activeARI consolidates enforcement across the generics landscape in one coordinated action
By filing simultaneously against 13 generic entrants and securing rapid consolidation, American Regent has efficiently centralised its Hatch-Waxman enforcement. A successful outcome in the consolidated action would operate against all defendants simultaneously. The 30-month regulatory stay triggered by timely Hatch-Waxman filing also provides ARI with market exclusivity protection while litigation proceeds.
Broad enforcement postureGeneric market entry for selenious acid IV solutions remains blocked pending outcome
With 13 generic ANDA filers now subject to consolidated litigation over US12150957B2, commercial launch of any competing selenious acid IV product is likely delayed pending court resolution. The coordinated nature of the filing suggests ARI views its patent position as strong enough to pursue the full generic landscape simultaneously — a posture that typically signals confidence in the asserted claims’ breadth and validity.
Market exclusivity at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and NDA holder — holder of US12150957B2 for selenious acid IV solutionSearch in Eureka ↗ |
| Defendant | Xiromed, LLC | Company | Generic pharmaceutical company and ANDA applicant for selenious acid 600 mcg/10 mL IV solutionSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | JOHN C. LEDDY | Attorney | Counsel for Xiromed, LLCSearch in Eureka ↗ |
| Defendant law firm | Nutter, McClennen & Fish LLP | Law Firm | Representing Xiromed, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is a procedural instrument, not a merits determination. The court’s order confirms that all December 13, 2024 actions — including this suit against Xiromed — share sufficient common questions of law and fact to warrant unified management. For Xiromed, this means no claims have been dismissed or adjudicated; infringement allegations under US12150957B2 remain fully at issue. The operative forum for all future developments is the consolidated docket, Civil Action No. 2:24-cv-7791.
US12150957B2 — Selenious Acid Intravenous Solution for Parenteral Nutrition
US12150957B2, filed under application number US18/672876, protects ARI’s selenious acid intravenous formulation delivering 600 mcg of selenium per 10 mL (60 mcg/mL). Selenious acid is a critical trace element supplement administered intravenously to patients receiving total parenteral nutrition (TPN), particularly those unable to absorb nutrients orally. The patent’s relatively recent application number suggests it may represent a continuation or reformulation patent within a broader patent family.
For the parenteral nutrition market, US12150957B2 is commercially significant: selenious acid IV solutions are standard-of-care components in TPN protocols across hospital and clinical settings. ARI’s decision to assert this patent against 13 generic manufacturers simultaneously suggests it covers formulation or manufacturing parameters broad enough to capture the commercially viable concentration range. Any company seeking to enter the selenious acid IV market — or already holding an ANDA — faces this patent as the primary exclusivity barrier until the consolidated litigation resolves or the patent is successfully challenged.
Should you run an FTO analysis against US12150957B2?
Any pharmaceutical manufacturer, CDMO, or TPN product supplier with current or planned activity in selenious acid IV formulations should treat US12150957B2 as a high-priority FTO target. With 13 ANDA filers already named as defendants, the asserted claim scope appears to cover the commercially standard 60 mcg/mL concentration. R&D teams developing alternative concentrations, formulations, or delivery formats should assess whether proposed products fall within or outside the asserted claim boundaries before advancing to regulatory filing.
PatSnap Eureka’s FTO Search Agent can map US12150957B2’s claim scope against your product specifications, identify the full patent family, surface any related continuations or divisional applications, and flag prior art that may inform invalidity arguments. For companies already named in the consolidated action, Eureka can also identify the prosecution history and claim amendments that shaped the patent’s current boundaries — critical intelligence for both litigation strategy and settlement positioning.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman IV formulation patent cases in the District of New Jersey
Explore parallel Hatch-Waxman ANDA litigation over parenteral and IV pharmaceutical formulation patents in the District of New Jersey.
What this case signals for the parenteral nutrition IP landscape
ARI’s simultaneous 13-defendant filing is a textbook Hatch-Waxman enforcement wave — and the consolidation outcome shapes how all generic entrants face the patent.
Simultaneous multi-defendant filing is a deliberate Hatch-Waxman litigation tactic
Filing against all ANDA applicants on the same day maximises the 30-month stay benefit and prevents any single generic from gaining a head start. Companies monitoring the parenteral nutrition space should track the consolidated docket (2:24-cv-7791) — not individual case numbers — for substantive developments on US12150957B2.
Consolidation accelerates claim construction — watch for a unified Markman hearing
With 13 defendants consolidated, a single Markman hearing will determine claim scope for all parties simultaneously. The outcome of that hearing is likely the pivotal event for generic market entry timelines. IP teams at generics manufacturers should monitor the consolidated docket for scheduling orders and briefing deadlines.
American v Xiromed — key questions answered
The case was consolidated because ARI filed 13 parallel infringement suits on the same date — December 13, 2024 — against different generic manufacturers over the same patent (US12150957B2) and the same product category. All parties jointly requested consolidation into In re Selenious Acid Litigation (2:24-cv-7791), citing common questions of law and fact. The court issued the consolidation order on January 3, 2025.
Yes. Consolidation does not terminate the underlying infringement claims. All claims against Xiromed under US12150957B2 remain active and will be litigated within the consolidated docket (2:24-cv-7791). The January 3, 2025 closure of the individual case number reflects a procedural merger, not a substantive disposition.
ARI asserts its branded selenious acid intravenous solution — delivering 600 mcg of selenium per 10 mL (60 mcg/mL) — as the commercial embodiment of US12150957B2. Xiromed’s accused product is its generic selenious acid 600 mcg Selenium/10 mL IV solution, which ARI alleges infringes the asserted patent claims.
The consolidation order covers 13 civil actions filed by ARI on December 13, 2024, plus the already-pending 2:24-cv-7791. Named defendants across the consolidated actions include Accord Healthcare, Aspiro Pharma, Cipla, Dr. Reddy’s, Gland Pharma, Hikma, RK Pharma, Somerset Therapeutics, Sun Pharma, Xiromed, and Zydus Pharmaceuticals, among others.
The 21-day closure does not reflect a rapid legal resolution on the merits. Rather, it reflects the efficiency of the consolidation mechanism — the parties and court moved quickly to merge all parallel actions under one docket. No claim construction, Markman hearing, summary judgment, or damages ruling occurred in this individual action. Substantive litigation continues in the consolidated proceeding.
PatSnap Eureka searches patents and litigation data to answer instantly.